The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Triplet vs quadruplet regimens for NDMM: selecting between these options
Shebli Atrash, MD, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the comparison between triplet and quadruplet regimens in newly diagnosed multiple myeloma (NDMM). Dr Atrash highlights that quadruplet regimens, particularly those including anti-CD38 monoclonal antibodies, have consistently shown superior efficacy and encourages clinicians to utilize quadruplets over triplets. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
